Key facts
- It has raised $170K; the latest was Early Stage VC in May 2025.
- Notable investors include Venture Kick, Kickfund, Venture (Switzerland).
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Nerai Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Nerai Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nerai Bio
Operator of a biotechnology company intended to focus on advancing genetic therapies. The company specializes in genetic medicine and advances therapies through protein engineering and artificial intelligence, enabling clients to enhance the development of next-generation therapeutic systems.
- Sector
- Healthcare
- HQ
- Zurich, Switzerland
- Employees
- 7
- Website
- nerai.bio/
- Ownership
- Privately Held (backing)
Nerai Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nerai Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nerai Bio in its N-PORT filings yet. We sweep new filings monthly.